Clinical Trial

Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression

Completed
View on ClinicalTrials.gov →
Summary
This study investigates the effects of the Ketoflex 12/3 diet on the clinical progression of early-to-mid stage Alzheimer's disease. The study evaluates cognitive function, metabolic changes, and overall health outcomes in participants following the Ketoflex 12/3 dietary protocol.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-20; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT06898424
Lead Sponsor Prof. Lutfu Hanoglu, MD
Conditions Alzheimer Type Dementia, Alzheimer's Disease (AD)
Enrollment 60 participants
Start Date 2024-03-01
Primary Completion 2024-09-30 (estimated)
Study Completion 2024-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24